These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35620187)

  • 61. Pre-Transplant Factors Influencing Rates of Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients.
    Zucker KM; Gomez PA; Kezirian O; Mehta S
    Gastroenterology Res; 2021 Jun; 14(3):190-193. PubMed ID: 34267835
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation.
    Zou WL; Zang YJ; Chen XG; Shen ZY
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):145-51. PubMed ID: 18397848
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Glutamate dehydrogenase and alkaline phosphatase as very early predictors of hepatocellular carcinoma recurrence after liver transplantation.
    Piras-Straub K; Khairzada K; Gerken G; Saner F; Treckmann J; Paul A; Canbay A; Herzer K
    Digestion; 2015; 91(2):117-27. PubMed ID: 25662469
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution.
    Cesario S; Genovesi V; Salani F; Vasile E; Fornaro L; Vivaldi C; Masi G
    Life (Basel); 2023 Jul; 13(7):. PubMed ID: 37511937
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
    Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
    JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients.
    Silverstein J; Roll G; Dodge JL; Grab JD; Yao FY; Mehta N
    Liver Transpl; 2020 Sep; 26(9):1100-1111. PubMed ID: 32531867
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study.
    Zheng L; Fang S; Wu F; Chen W; Chen M; Weng Q; Wu X; Song J; Zhao Z; Ji J
    Front Mol Biosci; 2020; 7():609322. PubMed ID: 33521054
    [No Abstract]   [Full Text] [Related]  

  • 69. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
    Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
    JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Follow-up Imaging After Liver Transplantation Should Take Into Consideration Primary Hepatocellular Carcinoma Characteristics.
    Dioguardi Burgio M; Ronot M; Fuks D; Dondero F; Cauchy F; Gaujoux S; Dokmak S; Paradis V; Durand F; Belghiti J; Vilgrain V
    Transplantation; 2015 Aug; 99(8):1613-8. PubMed ID: 25710611
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management.
    Kim S; Lim JU
    J Thorac Dis; 2022 May; 14(5):1684-1695. PubMed ID: 35693611
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma.
    Sposito C; Cucchetti A; Mazzaferro V
    Dig Dis Sci; 2019 Apr; 64(4):1001-1007. PubMed ID: 30852770
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
    de'Angelis N; Landi F; Carra MC; Azoulay D
    World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Liver transplantation for hepatic tumors: a systematic review.
    Ravaioli M; Ercolani G; Neri F; Cescon M; Stacchini G; Del Gaudio M; Cucchetti A; Pinna AD
    World J Gastroenterol; 2014 May; 20(18):5345-52. PubMed ID: 24833864
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival].
    Díaz-Sánchez A; Matilla A; Núñez O; Merino B; Peligros I; Rincón D; Salcedo M; Lo Iacono O; Vega Catalina M; Clemente G; Bañares R
    Gastroenterol Hepatol; 2010 Mar; 33(3):155-64. PubMed ID: 19945770
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma.
    Cheng JW; Shi YH; Fan J; Huang XW; Qiu SJ; Xiao YS; Wang Z; Dai Z; Tang ZY; Zhou J
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1445-53. PubMed ID: 21809031
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis.
    Deng HY; Chen ZJ; Qiu XM; Zhu DX; Tang XJ; Zhou Q
    Nutrition; 2021 Oct; 90():111345. PubMed ID: 34166897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.